Department of Psychiatry

Close

We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.

• The 401 Study is a randomized, double-blind, placebo-controlled  research study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression.

You may be able to take part in the 401 or 402 Study if you:

• are between 18 and 65 years of age (inclusive)
• have been diagnosed with bipolar I or bipolar II disorder
• are currently having a major depressive episode that started at least 2 weeks ago, but no more than
  6 months ago
• have previously had at least one bipolar manic episode or mixed episode (if you have bipolar I disorder) or hypomanic episode (if you have bipolar II disorder).

Study participation will last up to 12 weeks and will require nine visits to the study center.

Participate

Close

We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.

• The 402 study is a randomized, double-blind, placebo-controlled research study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression, when it is added to existing treatment with a mood stabilizer, specifically lithium or valproate.

You may be able to take part in the 401 or 402 Study if you:

• are between 18 and 65 years of age (inclusive)
• have been diagnosed with bipolar I or bipolar II disorder
• are currently having a major depressive episode that started at least 2 weeks ago, but no more than
  6 months ago
• have previously had at least one bipolar manic episode or mixed episode (if you have bipolar I disorder) or hypomanic episode (if you have bipolar II disorder).

Study participation will last up to 12 weeks and will require nine visits to the study center.

Participate

Close

We are looking for people who are currently experiencing major depressive episode to take part in this depression study. This clinical research study is designed to help us learn more about the efficacy of three treatment options for depression.

• The ASCERTAIN-TRD study is a multi-site, randomized, open-label study to compare the efficacy of  a) aripiprazole added to the current antidepressant, b) rTMS added to the current antidepressant, and c) switching to venlafaxine XR.

You may be able to take part in this study if you:

• are between 18 and 80 years of age (inclusive)
• have been diagnosed with major depressive disorder
• are currently experiencing depressive symptoms
• are currently on an antidepressant medication but haven’t experienced at least 50 % improvement in your symptoms
• have tried at least 1 other antidepressant medication but did not experience at least 50 % improvement in your symptoms

The study doctor will discuss additional requirements for being in the study with you.

Study participation will last up to 12 weeks and will require visits to the study center.

Participate

Close

We are looking for people who are currently experiencing major depressive episode to take part in this depression study. This clinical research study is designed to help us learn more about the efficacy of pimavanserin in treatment of depression.

• This study is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotoninnorepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder who had inadequate response to antidepressant therapy.

You may be able to take part in this study if you:

• are 18 years and older (inclusive)
• have been diagnosed with major depressive disorder
• are currently experiencing depressive symptoms
• are currently taking one of the following SSRI or SNRIs without experiencing at least 50 % improvement in your symptoms: "Citalopram, Escitalopram, Paroxetine, Fluoxetine, Sertraline, Duloxetine, Venlafaxine, Desvenlafaxine, Venlafaxine"

The study doctor will discuss additional requirements for being in the study with you.

Study participation will last up to 17 weeks and will require visits to the study center.

Participate

Close

We are currently enrolling participants for a clinical research study to look at the effectiveness and safety of an investigational medication AXS-05 (a combination of bupropion and dextromethorphan) compared to bupropion (Approved by FDA), in patients with depression who have not responded to prior treatment with at least one antidepressant.

Study participation will last up to 14 weeks which will include 2 weeks screening period, 6 weeks open label period (all the patients will receive bupropion), and 6 weeks double blind period (randomized either to bupropion or study medication).

You may be able to take part in this study if you are:

• Between 18 and 65 years of age 
• Diagnosed with depression
• Experiencing depression symptoms despite having taken one or two antidepressant medications in the past
• Able to provide written consent to participate in the study

The study doctor will discuss additional requirements for being in the study with you. If you are eligible for this study and choose to participate, you will receive all study visits and study-related medical care at no cost to you. Compensation for your time and travel may also be provided.

Participate

Close

We are looking for people who are currently experiencing insomnia to take part in this study. This clinical research study is designed to help us learn more about delivering Cognitive Behavioral Therapy for insomnia (CBT-I) by telemedicine, also known as video chat. Some participants receive in-person CBT-I while others receive CBT-I online.

If you are:

• 21-50 years old
• Have been experiencing insomnia for at least 3 months
• Are otherwise healthy

Then you may be eligible to participate in this research study!

Eligible participants will receive 6-8 weeks of Cognitive Behavioral Therapy for insomnia, provide up to 3 blood samples, answer several short questionnaires, fill out a daily sleep diary, and complete follow-up assessments. Total duration of participation varies between 5-7 months.

Participate

Close

The purpose of this study is to better understand how one night of sleep deprivation affects mood in people with depression using brain imaging by comparing individuals with current depression and healthy controls with no history of depression.

If you are:

• Between the ages of 21 and 50
• Currently experiencing depression
• Willing to spend 5 days at the Hospital of the University of Pennsylvania

You may be eligible for one of our current research studies.

Eligible participants will be asked to complete a number of questionnaires and computerized tests, provide blood and saliva samples, and undergo 3 MRIs.

Participate

Close